Investor Presentaiton

New product portfolio significantly de-risked with important catalysts ahead Milestones Achieved CAMZYOS™ ✓ Camzyos oHCM Future Catalysts • Camzyos nHCM $25B+ Non-Risk Adjusted* Opdualag Milestones Achieved Future Catalysts Breyanzi Opdualag 1L Mel FDC • Opdualag 1L NSCLC Milestones Achieved Breyanzi 3L+ LBCL ✓ Breyanzi 2L LBCL Future Catalysts $4B+ CAMZYOS™ Breyanzi 3L+ CLL . Breyanzi 3L+ iNHL • Opdualag Adj. Mel Opdualag 2L+ MSS CRC $4B+ Opdualag Milestones Achieved SOTYKTU Sotyktu PsO Future Catalysts • Sotyktu PsA • Sotyktu SLE Milestones Achieved Future Catalysts $4B+ SOTYKTUO ZEPOSIA. Zeposia MS ⚫ Zeposia CD ✓ Zeposia UC Milestones Achieved Abecma ✓ Abecma 5L+ Milestones Achieved Reblozyl 2L TD MDS Future Catalysts ✓ Abecma 3-5L ⚫ Reblozyl MF Reblozyl ✓ Reblozyl 1L MDS Ill Bristol Myers Squibb™ *Non-risk adjusted revenue potential, subject to positive registrational trials and health authority approval Note: Onureg & Inrebic <$1B NRA Financial projections may contain non promoted sales, BMS promotes only according to label $4B+ Reblozyl $3B+ Breyanzi $3B+ once-daily ZEPOSIA. $1B+ Abecma 2030 Not for Product Promotional Use 138

View entire presentation